ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID

– Concurrently, the Company Has Issued a Press Release Announcing the Presentation of Clinical Experience Data for NUPLAZID at the American Academy of Neurology (AAN) Annual Meeting SAN DIEGO–(BUSINESS WIRE)–Apr. 27, 2018– ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today issued the following statement: NUPLAZID® (pimavanserin) is

ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting

Two Independent Data Sets Confirm NUPLAZID Is Well-Tolerated and Efficacious in Treating Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis SAN DIEGO–(BUSINESS WIRE)–Apr. 27, 2018– ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines

PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease

Results underscore need for greater awareness of non-movement symptoms this Parkinson’s Disease Awareness Month TUCSON, Ariz. & SAN DIEGO–(BUSINESS WIRE)–Apr. 23, 2018– As part of Parkinson’s Disease Awareness Month, the Parkinson & Movement Disorder Alliance (PMDAlliance) and ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD) today announced the results